BMO Capital Markets reiterated coverage on BioNTech
$BNTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
BMO Capital Markets reiterated coverage of BioNTech with a rating of Outperform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/27/2026 | $135.00 | Neutral → Buy | UBS |
| 5/22/2026 | $96.00 | Mkt Perform | Bernstein |
| 2/2/2026 | $113.00 | Outperform → Market Perform | Leerink Partners |
| 1/16/2026 | $142.00 | Neutral → Buy | Goldman |
| 6/5/2025 | $134.00 → $145.00 | Buy | H.C. Wainwright |
| 5/29/2025 | $110.00 | Neutral | Goldman |
| 3/13/2025 | $145.00 | Buy | Citigroup |
| 1/10/2025 | $172.00 | Buy | Truist |
UBS upgraded BioNTech from Neutral to Buy and set a new price target of $135.00
Bernstein initiated coverage of BioNTech with a rating of Mkt Perform and set a new price target of $96.00
Leerink Partners downgraded BioNTech from Outperform to Market Perform and set a new price target of $113.00
DENVER, June 03, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted therapies have transformed outcomes for patients across multiple tumor types. Yet one of oncology's greatest challenges remains largely unsolved. Glioblastoma. Despite billions of dollars invested in research and development, glioblastoma remains one of the deadliest forms of cancer, with patients often facing limited treatment options and poor long-term survival rates. The disease's aggressive nature, combined with the difficulty of delivering therapies into the brain, has mad
First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1 expression levels and subtypes, highlighting its potential to set a new standard of carePumitamig plus chemotherapy showed robust and consistent antitumor activity in first-line non-small cell lung cancer at both evaluated dose levels, with higher confirmed objective response rates at the lower dose of 63.6% in the non-squamous and 72.7% in the squamous subtypesPumitamig is advancing through a comprehensive global Phase 3 development program in non-small cell lung cancer, including the actively
Pumitamig data from the ongoing Phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer mark the third global data set to consistently show encouraging anti-tumor activity for pumitamig in combination with chemotherapyGotistobart Phase 2 overall survival data in patients with platinum-resistant ovarian cancer add to the growing body of evidence supporting its potential as a chemotherapy-free treatment optionContinued advancement of late-stage oncology pipeline with 25+ Phase 2 and Phase 3 clinical trials, including 13 ongoing pivotal trials as well as novel-novel combination trials across major cancer types MAINZ, Germany, May 22, 2026 – BioNTech SE (NASDAQ:BNTX, "BioNTech"
6-K - BioNTech SE (0001776985) (Filer)
6-K - BioNTech SE (0001776985) (Filer)
6-K - BioNTech SE (0001776985) (Filer)
4 - BioNTech SE (0001776985) (Issuer)
4 - BioNTech SE (0001776985) (Issuer)
4 - BioNTech SE (0001776985) (Issuer)
Mainz, Germany, January 28, 2026 (GLOBE NEWSWIRE) – BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) announced today that the Supervisory Board has appointed Kylie Jimenez to the Management Board as Chief People Officer ("CPO") effective March 1, 2026. The appointment is in line with BioNTech's strategy to become a multi-product oncology company by 2030 and underscores the importance of its global, highly skilled workforce in achieving this objective. In the newly created Management Board role, Kylie Jimenez will be responsible for shaping and leading BioNTech's people strategy and its execution in alignment with the Company's priorities and business goals. She will focus on attractin
VANCOUVER, British Columbia, Jan. 14, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – The global immuno-oncology market is set to explode from its current $35 billion level to a massive $185.69 billion by 2035 as the industry moves toward the coordinated activation of the immune system[1]. This surge is being accelerated by the $69.16 billion genomics revolution, which is now integrating advanced profiling into every oncology workflow to pick winning treatments[2]. This strategic push for registration-ready precision assets fuels the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), ImmunityBio (NASDAQ:IBRX), OS Therapies (NYSE-A: OSTX), BioNTech SE (NASDAQ:BNTX),
MAINZ, Germany, October 28, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")), will host an edition of the Company's Innovation Series R&D Day at 09:00 a.m. Eastern Standard Time (3:00 p.m. CET) on Tuesday, November 11, 2025 in New York City, U.S. On the day, members of BioNTech's leadership team will provide an overview of the Company's strategy and clinical progress across its pipeline. Investors, analysts and the interested public are invited to join the event online via this link. A replay of the webcast will be available shortly after the conclusion of the event and archived on the Company's website for one year following the call. The public may also
SC 13G/A - BioNTech SE (0001776985) (Subject)
SC 13D - BioNTech SE (0001776985) (Filed by)
SC 13G/A - BioNTech SE (0001776985) (Subject)
Five additional pivotal trials for pumitamig initiated during 2026 in collaboration with Bristol Myers SquibbOncology pipeline strength and combination strategy highlighted through multiple clinical data updates, including pumitamig, gotistobart and antibody-drug conjugate programsCatalyst-rich year ahead with six late-stage pipeline data readouts expected across immunomodulators, antibody-drug conjugate and mRNA cancer immunotherapiesCOVID-19 2026/2027 season variant-adapted vaccine development and commercial preparation underwayOperational efficiency to be enhanced through manufacturing footprint consolidation, supporting strategic capital allocation to further advance its growing oncology
MAINZ, Germany, April 21, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) will announce its financial results for the first quarter 2026 on Tuesday, May 5, 2026. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (2:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will be available via this l
BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies Increased focus on PD-L11/VEGF-A bispecific immunomodulator pumitamig with eight global Phase 3 clinical trials planned to be ongoing for year-end in collaboration with Bristol Myers Squibb Full year 2025 revenues of €2.9 billion2, net loss of €1.1 billion (adjusted3 net loss of €0.1 billion) and diluted loss per share of €4.70 ($5.314) (adjusted3 diluted loss per share of €0.48 ($0.554)) Strong financial position continues to de-risk execution with cash, cash equivalents and security investments of €17.2 billion5Expect 202